Ibfla GEL Gel
Diclofenac Sodium 1% Topical
1.0%W/W
Arya Pharma Lab Pvt. Ltd.
| Pack size | 30gm |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 85.00 NPR |
Available as:
Indications
Ibfla GEL Gel is used for:
Rheumatoid arthritis, Osteoarthritis, Joint and muscular pains
Adult Dose
Topical/Cutaneous
Osteoarthritis
Adult: Apply 2 g (upper extremities)/4 g (lower extremities) q6hr
Not to exceed 8 g/day to any single joint of (upper) extremities; 16 g/day to any single joint of (lower extremities)
Local symptomatic relief of pain and inflammation
Adult: As diclofenac Na (1% gel): Apply onto affected area 3 or 4 times daily.
Child Dose
Safety and efficacy not established
Renal Dose
Administration
Apply to clean, dry skin
Avoid showering/bathing until gel/solution is dry for at least 30 min
Wash hands after use
Avoid clothing on knees until gel/solution is dry
Contra Indications
Contraindicated to the patients hypersensitive to any ingredient of the products. Peptic ulcer, hypersensitivity to Diclofenac like other non-steroid anti-inflammatory agents, Diclofenac is also contra-indicated in asthmatic patient in whom attack with asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or by other drugs with prostaglandin synthetase inhibitor. Gel should not be used under occlusive airtight dressings.
Precautions
In rare instances where peptic ulceration or gastro-intestinal bleeding occurs in patients under treatment with Diclofenac. In patients with advanced age should be kept under close observation.Gel should not be allowed to come in contact with the eyes or mucus membranes, after application the hands should be washed properly and not to be taken by mouth.
Lactation: Excretion in milk unknown/not recommended
Pregnancy-Lactation
Pregnancy Category: 1st and 2nd trimesters - C; category D during 3rd trimester because of risk for premature closure of the ductus arteriosus
Interactions
May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
Adverse Effects
Side effects of Diclofenac Sodium 1% Topical :
>10%
Dry skin (25-27%),Rash (20-35%),Contact dermatitis (19-33%),Pain (15-26%),Paresthesia (<20%),Pruritus (52%),Exfoliation (6-24%)
1-10%
Hypertension,Chest pain,Skin ulcer,Diarrhea,Dyspepsia,Alepesia,Photosensitivity,Edema,Conjunctivitis,Hematuria,Asthma,Pneumonia
Mechanism of Action
Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. Inhibits cyclooxygenase (COX)-1 and COX-2, thereby inhibiting prostaglandin synthesis. May also inhibit neutrophil aggregation/activation, inhibit chemotaxis, decrease proinflammatory cytokine level, and alter lymphocyte activity.
Note
Ibfla GEL 1.0%W/W Gel manufactured by Arya Pharma Lab Pvt. Ltd.. Its generic name is Diclofenac Sodium 1% Topical. Ibfla GEL is availble in Nepal.
Farmaco Nepal drug index information on Ibfla GEL Gel is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.